Diagnostic markers for Parkinson's disease

Current Opinion in Neurology

Volumn 24, Issue 4, 2011, Pages 309-317

  Chahine, Lama M ^a   Stern, Matthew B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

biomarker; Parkinson's at risk syndrome; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ALPHA SYNUCLEIN; DJ 1 PROTEIN; IOFLUPANE I 123;

AUTONOMIC NERVOUS SYSTEM; BRADYKINESIA; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC ACCURACY; DOPPLER ECHOGRAPHY; EARLY DIAGNOSIS; GENETIC ANALYSIS; HUMAN; NARCOLEPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLFACTORY SYSTEM; PARKINSON DISEASE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC INNERVATION;

BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; DIAGNOSTIC TESTS, ROUTINE; HUMANS; PARKINSON DISEASE; RISK FACTORS;

EID: 79960843923     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283461723     Document Type: Review

References (116)

1. Langston JW, Koller WC. The next frontier in Parkinson's disease: presymptomatic detection. Neurology 1991; 41:5-7.
2. Siderowf A, Stern MB. Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. Ann Neurol 2008; 64 (Suppl 2): S139-S147.
3. Siderowf A, Stern MB. Preclinical diagnosis of Parkinson's disease: are we there yet? Curr Neurol Neurosci Rep 2006; 6:295-301. (Pubitemid 44069968)
4. DelleDonne A, Klos KJ, Fujishiro H, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008; 65:1074-1080.
5. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184.
6. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 2001; 57:S34-S38.
7. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125:861-870. (Pubitemid 34279780)
8. Suchowersky O, Reich S, Perlmutter J, et al. Quality Standards Subcommittee of the American Academy of Neurology Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:968-975. (Pubitemid 44044778)
9. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008; 129:526-529. (Pubitemid 352029270)
10. Muller A, Mungersdorf M, Reichmann H, et al. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002; 9:521-524.
11. Doty RL, Golbe LI, McKeown DA, et al. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 1993; 43:962-965. (Pubitemid 23150569)
12. Wenning GK, Shephard B, Hawkes C, et al. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995; 91:247-250.
13. Nagayama H, Hamamoto M, Ueda M, et al. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76:249-251. (Pubitemid 40143717)
14. Braune S, Reinhardt M, Schnitzer R, et al. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53:1020-1025. (Pubitemid 29442118)
15. Lipp A, Sandroni P, Ahlskog JE, et al. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 2009; 66:742-750.
16. Goldstein DS, Holmes C, Bentho O, et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008; 14:600-607.
17. Borroni B, Malinverno M, Gardoni F, et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 2008; 71:1796-1803.
18. Brettschneider J, Petzold A, Sussmuth SD, et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord 2006; 21:2224-2227. (Pubitemid 46140444)
19. Mata IF, Shi M, Agarwal P, et al. SNCA variant associated with Parkinson disease and plasma a-synuclein level. Arch Neurol 2010; 67:1350-1356.
20. Abdo WF, Bloem BR, Van Geel WJ, et al. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007; 28:742-747. (Pubitemid 46349352)
21. Walter U, Niehaus L, Probst T, et al. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003; 60:74-77. (Pubitemid 36070647)
22. Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 2005; 76:423-425. (Pubitemid 40299138)
23. Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol 2007; 64:1635-1640. (Pubitemid 350106766)
24. Jennings DL, Seibyl JP, Oakes D, et al. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004; 61:1224-1229. (Pubitemid 39062674)
25. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28:266-272.
26. Asenbaum S, Pirker W, Angelberger P, et al. 123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998; 105: 1213-1228. (Pubitemid 29017402)
27. Righini A, Antonini A, Ferrarini M, et al. Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease. J Comput Assist Tomogr 2002; 26:266-271. (Pubitemid 34233376)
28. Rizzo G, Martinelli P, Manners D, et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 2008; 131:2690-2700.
29. Kollensperger M, Seppi K, Liener C, et al. Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 2007; 22:1771-1776. (Pubitemid 47597601)
30. Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006; 129:2679-2687. (Pubitemid 44522101)
31. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41:58-64. (Pubitemid 27057093)
32. Bohnen NI, Kuwabara H, Constantine GM, et al. Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. Neurosci Lett 2007; 424:185-189. (Pubitemid 47404756)
33. Bohnen NI, Studenski SA, Constantine GM, Moore RY. Diagnostic performance of clinical motor and nonmotor tests of Parkinson disease: a matched case-control study. Eur J Neurol 2008; 15:685-691. (Pubitemid 351814401)
34. Blekher T, Weaver M, Rupp J, et al. Multiple step pattern as a biomarker in Parkinson disease. Parkinsonism Relat Disord 2009; 15:506-510.
35. Watts RL, Mandir AS, Ahn KJ, et al. Electrophysiologic analysis of early Parkinson's disease. Neurology 1991; 41:44-48; discussion 48-49.
36. Przuntek H. Early diagnosis in Parkinson's disease. J Neural Transm Suppl 1992; 38:105-114. (Pubitemid 23026849)
37. Koller WC, Montgomery EB. Issues in the early diagnosis of Parkinson's disease. Neurology 1997; 49:S10-S25. (Pubitemid 27304768)
38. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110:517-536. (Pubitemid 36543283)
39. Menza MA, Mark MH, Burn DJ, Brooks DJ. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995; 7:176-179.
40. Poewe W, Karamat E, Kemmler GW, Gerstenbrand F. The premorbid personality of patients with Parkinson's disease: a comparative study with healthy controls and patients with essential tremor. Adv Neurol 1990; 53:339-342.
41. Eatough VM, Kempster PA, Stern GM, Lees AJ. Premorbid personality and idiopathic Parkinson's disease. Adv Neurol 1990; 53:335-337.
42. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005; 65:1442-1446. (Pubitemid 41552777)
43. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001; 57:456-462. (Pubitemid 32757593)
44. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66:845-851. (Pubitemid 43739758)
45. Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. Brain 2009; 132:3298-3307.
46. Postuma RB, Gagnon JF, Rompre S, Montplaisir JY. Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology 2010; 74:239-244.
47. Valappil RA, Black JE, Broderick MJ, et al. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord 2010; 25:2296-2303.
48. Sauvageot N, Vaillant M, Diederich NJ. Reduced sympathetically driven heart rate variability during sleep in Parkinson's disease: a case-control polysomnography-based study. Mov Disord 2011; 26:234-240.
49. Ansari KA, Johnson A. Olfactory function in patients with Parkinson's disease. J Chronic Dis 1975; 28:493-497.
50. Doty RL, Bromley SM, Stern MB. Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria. Neurodegeneration 1995; 4:93-97.
51. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984; 32:489-502. (Pubitemid 14148126)
52. Kobal G, Hummel T, Sekinger B, et al. Sniffin' sticks': screening of olfactory performance. Rhinology 1996; 34:222-226. (Pubitemid 27090599)
53. Hummel T, Sekinger B, Wolf SR, et al. 'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 1997; 22: 39-52. (Pubitemid 27142122)
54. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988; 38:1237-1244.
55. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001; 16:41-46. (Pubitemid 36041112)
56. Siderowf A, Newberg A, Chou KL, et al. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 2005; 64:1716-1720. (Pubitemid 40695804)
57. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008; 63:167-173. (Pubitemid 351355295)
58. Berendse HW, Booij J, Francot CM, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001; 50:34-41. (Pubitemid 32591460)
59. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56:173-181. (Pubitemid 39037913)
60. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology 2009; 72:S21-S26.
61. Katzenschlager R, Zijlmans J, Evans A, et al. Olfactory function distinguishes vascular parkinsonism from Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:1749-1752. (Pubitemid 39611479)
62. Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch Neurol 1998; 55:84-90. (Pubitemid 28139109)
63. Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBGSPECT. J Neurol Sci 2000; 175:3-12. (Pubitemid 30227477)
64. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 metaiodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155:60-67. (Pubitemid 28141060)
65. Barbic F, Perego F, Canesi M, et al. Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension. Hypertension 2007; 49:120-126. (Pubitemid 46360350)
66. Winkler S, Hagenah J, Lincoln S, et al. Alpha-synuclein and Parkinson disease susceptibility. Neurology 2007; 69:1745-1750.
67. Tan EK, Chai A, Teo YY, Zhao Y, et al. Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 2004; 62:128-131. (Pubitemid 38082887)
68. Yu L, Xu P, He X, et al. SNP rs7684318 of the alpha-synuclein gene is associated with Parkinson's disease in the Han Chinese population. Brain Res 2010; 1346:262-265.
69. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41:1308-1312.
70. Scherzer CR, Eklund AC, Morse LJ, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci USA 2007; 104:955-960. (Pubitemid 46154718)
71. Shehadeh LA, Yu K, Wang L, et al. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease. PLoS One 2010; 5:e9104.
72. Gasser T. Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects Prog. Brain Res 2010; 183:3-20.
73. Gasser T. Genomic and proteomic biomarkers for Parkinson disease. Neurology 2009; 72:S27-S31.
74. Shi M, Zabetian CP, Hancock AM, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 2010; 480:78-82.
75. Guo J, Sun Z, Xiao S, et al. Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients. Cell Res 2009; 19:1401-1403.
76. Goldknopf IL, Bryson JK, Strelets I, et al. Abnormal serum concentrations of proteins in Parkinson's disease. Biochem Biophys Res Commun 2009; 389:321-327.
77. Eller M, Williams DR. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol 2009; 5:561-570.
78. Chen-Plotkin AS, Hu WT, Siderowf A, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2010 [Epub ahead of print].
79. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008; 131:389-396. (Pubitemid 351197614)
80. Ahmed SS, Santosh W, Kumar S, Christlet HT. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci 2009; 16:63.
81. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alphasynuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008; 213:315-325.
82. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006; 349:162-166. (Pubitemid 44331776)
83. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133:713-726.
84. Borghi R, Marchese R, Negro A, et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000; 287:65-67. (Pubitemid 30332379)
85. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of asynuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010; 16:1766-1772.
86. Waragai M, Wei J, Fujita M, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006; 345:967-972. (Pubitemid 43776502)
87. Bibl M, Mollenhauer B, Esselmann H, et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006; 129:1177-1187.
88. Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000; 54:1875-1876. (Pubitemid 30428428)
89. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid b1-42 predicts cognitive decline in Parkinson disease. Neurology 2010; 75:1055-1061.
90. Carlsson A, Fornstedt B. Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease. Neurology 1991; 41:50-51; discussion 52.
91. Michell AW, Luheshi LM, Barker RA. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett 2005; 381:294-298. (Pubitemid 40719174)
92. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006; 20:419-425. (Pubitemid 44933318)
93. Mollenhauer B, Trenkwalder C. Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord 2009; 24:1411-1426.
94. Maita C, Tsuji S, Yabe I, et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 2008; 431:86-89.
95. Schiess M, Oh I. Serum uric acid and clinical progression in Parkinson disease: potential biomarker for nigrostriatal failure. Arch Neurol 2008; 65:698-699. (Pubitemid 351831445)
96. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001; 56:13-17. (Pubitemid 32059645)
97. Becker G, Seufert J, Bogdahn U, et al. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995; 45:182-184.
98. Zecca L, Berg D, Arzberger T, Ruprecht P, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005; 20:1278-1285. (Pubitemid 41645902)
99. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59:999-1005. (Pubitemid 34640761)
100. Berg D, Hochstrasser H, Schweitzer KJ, Riess O. Disturbance of iron metabolism in Parkinson's disease: ultrasonography as a biomarker. Neurotox Res 2006; 9:1-13.
101. Prestel J, Schweitzer KJ, Hofer A, et al. Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. Mov Disord 2006; 21:1763-1765. (Pubitemid 44742216)
102. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004; 19:1196-1202. (Pubitemid 39429962)
103. Liepelt I, Behnke S, Schweitzer K, et al. Premotor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging 2009 [Epub ahead of print].
104. Berg D. Transcranial ultrasound as a risk marker for Parkinson's disease. Mov Disord 2009; 24 (Suppl 2):S677-S683.
105. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996; 47:718-726. (Pubitemid 26307303)
106. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996; 40:873-884. (Pubitemid 27044605)
107. Brucke T, Asenbaum S, Pirker W, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997; 50:9-24.
108. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34:423-431. (Pubitemid 23259619)
109. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46:231-237.
110. Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45:577-582. (Pubitemid 29217585)
111. Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007; 7:27.
112. Deeb J, Shah M, Muhammed N, et al. A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson's disease. QJM 2010; 103:941-952.
113. Cruz CJ, Aminoff MJ, Meyerhoff DJ, et al. Proton MR spectroscopic imaging of the striatum in Parkinson's disease. Magn Reson Imaging 1997; 15:619-624. (Pubitemid 27366741)
114. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008; 70:1411-1417. (Pubitemid 351521933)
115. Peran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010; 133:3423-3433.
116. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009; 72:1378-1384.